On September 3rd, Ma Jian, Co-founder and CEO of XTALPI, led a delegation to visit Guangzhou Pharma Group. Chen Jiehui, Deputy Party Secretary, Vice Chairman, and General Manager of Guangzhou Pharma Group, along with relevant departments and representatives from subsidiaries including Guangzhou Pharma Research Institute, Baiyunshan Heijigong, Baiyunshan Zhongyi Qixing, Baiyunshan Hanfang, Baiyunshan Pharmaceutical General Factory, and Baiyunshan Hutchison Whampoa Traditional Chinese Medicine, participated in the exchange meeting.
During the symposium, XTALPI executives provided detailed presentations on the company's technological advantages and innovative achievements in small molecule platforms, automation platforms, and AI-enabled traditional Chinese medicine. Subsequently, both parties engaged in in-depth discussions around four major cooperation directions:
First, drug discovery service cooperation, where XTALPI would provide discovery support for small molecule chemical drugs and large molecule biologics for Guangzhou Pharma Group. Second, joint advancement of quality projects, with XTALPI focusing on front-end drug development while Guangzhou Pharma Group leverages its core brand competitiveness and full industry chain advantages to collaboratively advance project implementation. Third, AI + Traditional Chinese Medicine cooperation, integrating Guangzhou Pharma Group's resources with XTALPI to build databases, conduct traditional Chinese medicine R&D and upgrade production manufacturing hardware platforms, while utilizing AI technology to optimize traditional Chinese medicine compound formulations and screen effective ingredient combinations to support new traditional Chinese medicine drug development. Fourth, industrialization cooperation, where both parties explore advancing industrialization and commercialization of quality projects.
Chen Jiehui expressed gratitude for XTALPI's presentation and introduced Guangzhou Pharma Group's business segments, development directions, and scientific research innovation initiatives. He stated that innovation is both the driving force and core competitiveness of enterprise development. Guangzhou Pharma Group is actively promoting new quality innovation, international expansion, capital operations, digital transformation, and modern management. In recent years, through increased R&D investment, the company has actively built "Digital Smart Guangzhou Pharma," establishing traditional Chinese medicine intelligent traceability systems, intelligent production lines, smart pharmacies, and pharmaceutical intelligent logistics centers.
As an excellent intelligent and automation-driven pharmaceutical R&D technology company, XTALPI can further strengthen communication and consultation with Guangzhou Pharma Group. Both parties can establish cooperation mechanisms around key directions in priority industrial areas, opening a new chapter of mutually beneficial and innovation-empowering cooperation.
Ma Jian stated that as one of the early technology companies to develop artificial intelligence technology, XTALPI has consistently adhered to independent innovation. Relying on cutting-edge technologies such as artificial intelligence and quantum physics, the company has independently developed internationally competitive products including molecular force field models, crystal form prediction models, generative molecular models for drugs, and intelligent autonomous experimental platforms. These innovations are closely integrated with industry applications, achieving implementation in scenarios such as new drug development, new materials, and modernization of traditional Chinese medicine.
As a leading enterprise in China's pharmaceutical and health industry, Guangzhou Pharma Group has cultivated the traditional Chinese medicine field for many years with solid industrial foundations and broad cooperation prospects. He hopes both parties can leverage their respective advantages, explore new cooperation models, and achieve win-win development.
This exchange created opportunities for both parties to enhance understanding and explore future cooperation. Guangzhou Pharma Group will actively utilize AI technology to empower innovative R&D, using new quality productive forces to promote high-quality development of the biomedical industry.